As the metabolic hub for essential energy substances such as lipids and glucose, mitochondria play crucial roles in processes like hepatic stellate cell activation, insulin resistance, and inflammation. Consequently, mitochondria significantly contribute to the development of fibrosis, steatosis, tumors, and other diseases involving metabolic reprogramming. When mitochondrial function and dynamics are severely compromised, mitochondrial DNA (mtDNA) stability becomes particularly susceptible to xenobiotic exposure and other pathology stimulus. During these pathological cascades, mitochondrial dysfunction exacerbates disease progression through the accumulation of oxidative stress and the release of mtDNA, thereby worsening clinical outcomes. Recent research has emphasized the importance of mitochondria as pharmacological targets for the treatment of such digestive system diseases, such as inflammatory bowel diseases, mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), and irritable bowel syndrome, all of which are marked by gastrointestinal motility disorders.
The study of mitochondrial dysfunction has benefited significantly from advancements in multi-omics, which provide deeper insights into the distinct mtDNA gene expression and complex metabolic alterations accompanying these diseases. These technologies help elucidate the metabolic pathways disrupted by mitochondrial dysfunctions and identify potential biomarkers for disease diagnosis and treatment. Therefore, the therapeutic potential of targeting mitochondria has garnered increasing attention and shown promising results.
This Research Topic aims to provide a comprehensive and up-to-date collection of research articles, reviews, and viewpoints utilizing multi-omics to explore the role of mitochondrial dysfunctions in digestive system diseases and to develop new therapies targeting mitochondrial dysfunction. Metabolic reprogramming, mtDNA signaling, and oxidative stress injury - either following or causing mitochondrial dysfunction - are prominent hallmarks of inflammatory and malignant pathologies. By delineating the multi-omics alteration in mitochondria during the occurrence and progression of inflammatory bowel diseases (IBD), MNGIE, irritable bowel syndrome (IBS), liver fibrosis, steatosis, and other diseases and tumors in the digestive system, researchers are encouraged to propose comprehensive phenotyping of the diseases and develop novel therapy alternatives to these patients.
We welcome all the recent advances related to the below topics. Please follow the standard Frontiers submission guidelines for manuscript preparation and submission.
● Leveraging combined multi-omics to reveal the role of mitochondrial dysfunction in the progression of digestive system disease and metabolic abnormalities, including gastrointestinal motility disorders, liver fibrosis, steatosis, and digestive system malignancies.
● Exploring multi-omics analyses and machine learning to phenotype mitochondrial dysfunctions in digestive system diseases.
● Utilizing Spatial transcriptomics and single-cell sequencing to assess mitochondrial activity in different cell types within digestive system diseases.
● Investigating the combined use of mitochondrial inhibitors with other inhibitors to enhance treatment efficacy in digestive system diseases.
● Exploring the potential and perspectives of targeted mitochondrial transplantation in personalized therapy for curing digestive system diseases.
● Developing novel drugs, inhibitors, and therapies targeting mitochondria dysfunctions in digestive system disease.
Keywords:
Multi-omics Analyses, Mitochondrial Dysfunctions, Digestive System Diseases, Novel Therapy Alternatives
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
As the metabolic hub for essential energy substances such as lipids and glucose, mitochondria play crucial roles in processes like hepatic stellate cell activation, insulin resistance, and inflammation. Consequently, mitochondria significantly contribute to the development of fibrosis, steatosis, tumors, and other diseases involving metabolic reprogramming. When mitochondrial function and dynamics are severely compromised, mitochondrial DNA (mtDNA) stability becomes particularly susceptible to xenobiotic exposure and other pathology stimulus. During these pathological cascades, mitochondrial dysfunction exacerbates disease progression through the accumulation of oxidative stress and the release of mtDNA, thereby worsening clinical outcomes. Recent research has emphasized the importance of mitochondria as pharmacological targets for the treatment of such digestive system diseases, such as inflammatory bowel diseases, mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), and irritable bowel syndrome, all of which are marked by gastrointestinal motility disorders.
The study of mitochondrial dysfunction has benefited significantly from advancements in multi-omics, which provide deeper insights into the distinct mtDNA gene expression and complex metabolic alterations accompanying these diseases. These technologies help elucidate the metabolic pathways disrupted by mitochondrial dysfunctions and identify potential biomarkers for disease diagnosis and treatment. Therefore, the therapeutic potential of targeting mitochondria has garnered increasing attention and shown promising results.
This Research Topic aims to provide a comprehensive and up-to-date collection of research articles, reviews, and viewpoints utilizing multi-omics to explore the role of mitochondrial dysfunctions in digestive system diseases and to develop new therapies targeting mitochondrial dysfunction. Metabolic reprogramming, mtDNA signaling, and oxidative stress injury - either following or causing mitochondrial dysfunction - are prominent hallmarks of inflammatory and malignant pathologies. By delineating the multi-omics alteration in mitochondria during the occurrence and progression of inflammatory bowel diseases (IBD), MNGIE, irritable bowel syndrome (IBS), liver fibrosis, steatosis, and other diseases and tumors in the digestive system, researchers are encouraged to propose comprehensive phenotyping of the diseases and develop novel therapy alternatives to these patients.
We welcome all the recent advances related to the below topics. Please follow the standard Frontiers submission guidelines for manuscript preparation and submission.
● Leveraging combined multi-omics to reveal the role of mitochondrial dysfunction in the progression of digestive system disease and metabolic abnormalities, including gastrointestinal motility disorders, liver fibrosis, steatosis, and digestive system malignancies.
● Exploring multi-omics analyses and machine learning to phenotype mitochondrial dysfunctions in digestive system diseases.
● Utilizing Spatial transcriptomics and single-cell sequencing to assess mitochondrial activity in different cell types within digestive system diseases.
● Investigating the combined use of mitochondrial inhibitors with other inhibitors to enhance treatment efficacy in digestive system diseases.
● Exploring the potential and perspectives of targeted mitochondrial transplantation in personalized therapy for curing digestive system diseases.
● Developing novel drugs, inhibitors, and therapies targeting mitochondria dysfunctions in digestive system disease.
Keywords:
Multi-omics Analyses, Mitochondrial Dysfunctions, Digestive System Diseases, Novel Therapy Alternatives
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.